EARNINGS: Alliance Pharma swings to profit; DG Innovate loss widens
The following is a round-up of earnings for London-listed companies, issued on Monday and not separately reported by Alliance News: Alliance Pharma PLC - Chippenham, Wiltshire-based distributor of ...
Osisko to buy royalties on Western Australia's Dalgaranga gold project in $50M deal
Osisko Gold Royalties agrees to purchase royalties on Dalgaranga gold project in Western Australia, a promising high-grade ...
FDA approves PureTech’s KarXT to treat schizophrenia in adults
PureTech Health has obtained approval from the US Food and Drug Administration (FDA) for KarXT to treat schizophrenia in ...
Impacts17h
Poxel and OrbiMed Strike $50 Million Deal to Monetize TWYMEEG Royalties
Poxel has struck a $50 million deal with OrbiMed to monetize TWYMEEG royalties. Takeaway Points Poxel and OrbiMed Strike $50 ...
Poxel Announces Agreement with OrbiMed to Monetize a portion of TWYMEEG® Royalties for USD 50 million
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for ...
2 High-Yield Dividend Stocks Near 52-Week Lows: Are They Buys Now?
These dividend-paying stocks offer hard-to-find high yields, but that doesn't necessarily make them good stocks to buy now.
Pharmabiz2d
Evotec enters technology development partnership with Novo Nordisk in cell therapy
Evotec SE, a life science company, has entered a technology development partnership with Novo Nordisk in cell therapy. Both Evotec and Novo Nordisk have significant expertise and a strategic focus to ...
bovnews3d
Royalty Pharma plc (RPRX) Posted 30.07% Profit Margin Last Year—Can It Hold Up?
UBS has recently reduced Royalty Pharma plc (RPRX) stock to Neutral rating, as announced on June 3, 2024, according to Finviz. Earlier, on June 14, 2022, UBS had resumed the stock to Buy, setting a ...
MT Newswires on MSN3d
Bristol-Myers Squibb Gets FDA Approval for Schizophrenia Drug
Bristol-Myers Squibb (BMY) shares rose early Friday as the biopharmaceutical company obtained approval from the US Food and Drug Administration for its Cobenfy drug to treat schizophrenia in adults.
PureTech Health celebrates KarXT approval by FDA for schizophrenia
PureTech Health PLC on Friday said KarXT has received US Food & Drug Administration approval for treating schizophrenia. The Boston, Massachusetts-based biotechnology company said the milestone ...
FDA Approves KarXT To Treat Schizophrenia; PureTech Health Gets $29 Mln Milestone Payment
This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...
Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-Generation Cell Therapies
Both Evotec and Novo Nordisk have significant expertise and a strategic focus to support stem cell-based therapies. In order to provide next-generation off-the-shelf cell therapy products for clinical ...